Information Provided By: 
Fly News Breaks for June 8, 2018
TXMD
Jun 8, 2018 | 08:05 EDT
Cantor Fitzgerald analyst William Tanner views the recent FDA approval of Imvexxy as a major milestone for TherapeuticsMD that sets the company on a course to achieve long-term commercial viability. He reiterates an Overweight rating on the shares with a $26 price target. The investability of TherapeuticsMD stock "has increased considerably," Tanner tells investors in a research note. He believes the current stock price does not fully reflect the value of Imvexxy, "much less that of TX-001."
News For TXMD From the Last 2 Days
There are no results for your query TXMD
